Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
US OPEN: Blue Wave in Congress Triggers Massive Wall Street Rally, Dow Gains Over 1,000 Points
Market Wrap: European Stocks Rise Following US Elections
Spain Is Back on Its Feet 🚀 Trump's Nemesis Makes a Comeback After the Midterm Elections 📈
Novo Nordisk Earnings: Downtrend is slowing down